For a pediatric patient with Takayasu arteritis with persistent enhancement and mild progression on imaging after recent transition to tocilizumab (2 months), would you continue tocilizumab therapy, increase to q2 week dosing, or transition to cyclophosphamide?

1 Answers

Mednet Member

Rheumatology · Georgetown University

Would add to the methotrexate and steroids, shortened interval of the tocilizumab, followed by moving to Cytoxan. There is less experience with B-cell-targeted treatment, such as Rituxan or obinutuzumab, for cluster of differentiation 19 (CD19) or CD20.